Aposense
Aposense is a company that is evolving and becoming Interna, indicating a possible rebranding or transformation. The company's mission and vision are not explicitly detailed in the provided content.
Industries
Nr. of Employees
small (1-50)
Aposense
Products
Molecular Nano-Motors (MNMs)
A universal platform for delivering genetic drugs, such as siRNA, into cells by utilizing membrane electrical forces.
siRNA Delivery Platform
A delivery system that uses MNMs to transport siRNA into cell cytoplasm, enabling gene silencing for various therapeutic applications.
Antiviral Platform Technology
A technology that tailors siRNA sequences to target conserved viral genes, allowing rapid adaptation to mutagenesis and treatment of respiratory viruses.
ATT-11T
A novel lipophilic anti-cancer pro-drug that binds to cell membranes, forming an inactive pro-drug depot on tumor cells, providing a wider therapeutic window and milder adverse effects compared to irinotecan.
Pulmonary Therapeutics
siRNA-based treatments administered via inhalation or intranasal instillation to target respiratory diseases and viral infections.
Gastrointestinal Therapeutics
siRNA-based therapies targeting genes contributing to serious GI diseases, with preclinical work ongoing for clinical trials.
Molecular Nano-Motors (MNMs)
A universal platform for delivering genetic drugs, such as siRNA, into cells by utilizing membrane electrical forces.
siRNA Delivery Platform
A delivery system that uses MNMs to transport siRNA into cell cytoplasm, enabling gene silencing for various therapeutic applications.
Antiviral Platform Technology
A technology that tailors siRNA sequences to target conserved viral genes, allowing rapid adaptation to mutagenesis and treatment of respiratory viruses.
ATT-11T
A novel lipophilic anti-cancer pro-drug that binds to cell membranes, forming an inactive pro-drug depot on tumor cells, providing a wider therapeutic window and milder adverse effects compared to irinotecan.
Pulmonary Therapeutics
siRNA-based treatments administered via inhalation or intranasal instillation to target respiratory diseases and viral infections.
Gastrointestinal Therapeutics
siRNA-based therapies targeting genes contributing to serious GI diseases, with preclinical work ongoing for clinical trials.
Expertise Areas
- Brand transition